These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 9416837)

  • 1. The Myb leucine zipper is essential for leukemogenicity of the v-Myb protein.
    Bartůnek P; Karafiát V; Dvoráková M; Záhorová V; Mandíková S; Zenke M; Dvorák M
    Oncogene; 1997 Dec; 15(24):2939-49. PubMed ID: 9416837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The carboxy-terminal domain of c-Myb activates reporter gene expression in yeast.
    Seneca S; Punyammalee B; Sureau A; Perbal B; Dvorák M; Crabeel M
    Oncogene; 1993 Sep; 8(9):2335-42. PubMed ID: 8361752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FAETL motif required for leukemic transformation by v-Myb.
    Fu SL; Lipsick JS
    J Virol; 1996 Aug; 70(8):5600-10. PubMed ID: 8764074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A highly conserved cysteine in the v-Myb DNA-binding domain is essential for transformation and transcriptional trans-activation.
    Grässer FA; LaMontagne K; Whittaker L; Stohr S; Lipsick JS
    Oncogene; 1992 May; 7(5):1005-9. PubMed ID: 1570148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. tom-1, a novel v-Myb target gene expressed in AMV- and E26-transformed myelomonocytic cells.
    Burk O; Worpenberg S; Haenig B; Klempnauer KH
    EMBO J; 1997 Mar; 16(6):1371-80. PubMed ID: 9135152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation by Jun: requirement for leucine zipper, basic region and transactivation domain and enhancement by Fos.
    Morgan IM; Ransone LJ; Bos TJ; Verma IM; Vogt PK
    Oncogene; 1992 Jun; 7(6):1119-25. PubMed ID: 1594243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An ex vivo model to study v-Myb-induced leukemogenicity.
    Dvorakova M; Kralova J; Karafiat V; Bartunek P; Dvorak M
    Blood Cells Mol Dis; 2001; 27(2):437-45. PubMed ID: 11259166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The various domains of v-myb and v-ets oncogenes of E26 retrovirus contribute differently, but cooperatively, in transformation of hematopoietic lineages.
    Domenget C; Leprince D; Pain B; Peyrol S; Li RP; Stehelin D; Samarut J; Jurdic P
    Oncogene; 1992 Nov; 7(11):2231-41. PubMed ID: 1331935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TATA-box dependent trans-activation of the human HSP70 promoter by Myb proteins.
    Foos G; Natour S; Klempnauer KH
    Oncogene; 1993 Jul; 8(7):1775-82. PubMed ID: 8510924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociation of transcriptional activation and oncogenic transformation by v-Myb.
    Chen RH; Fields S; Lipsick JS
    Oncogene; 1995 Nov; 11(9):1771-9. PubMed ID: 7478605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nuclear oncogenes v-erbA and v-ets cooperate in the induction of avian erythroleukemia.
    Metz T; Graf T
    Oncogene; 1992 Mar; 7(3):597-605. PubMed ID: 1347919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive expression of full-length c-Myb transforms avian cells characteristic of both the monocytic and granulocytic lineages.
    Fu SL; Lipsick JS
    Cell Growth Differ; 1997 Jan; 8(1):35-45. PubMed ID: 8993832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional activation by human c-myb and v-myb genes.
    Kalkbrenner F; Guehmann S; Moelling K
    Oncogene; 1990 May; 5(5):657-61. PubMed ID: 2189102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming potential of truncated v-myb and stimulation of replication by gag-myb fusion products.
    Merzak A; Soret J; Martinerie C; Sureau A; Crochet J; Perbal B
    Oncogene; 1992 Mar; 7(3):535-42. PubMed ID: 1549366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weak transcriptional activation is sufficient for transformation by v-Myb.
    Engelke U; Whittaker L; Lipsick JS
    Virology; 1995 Apr; 208(2):467-77. PubMed ID: 7747419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone H3 tail positioning and acetylation by the c-Myb but not the v-Myb DNA-binding SANT domain.
    Mo X; Kowenz-Leutz E; Laumonnier Y; Xu H; Leutz A
    Genes Dev; 2005 Oct; 19(20):2447-57. PubMed ID: 16195416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BM2L is a spontaneous leukemogenic variant of a non-leukemogenic v-myb-transformed myeloid cell line.
    Bottazzi ME; Goodenow MM; Moscovici MG; Moscovici C
    Oncogene; 1993 Mar; 8(3):731-6. PubMed ID: 8437856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single amino-acid substitution in the DNA-binding domain of the myb oncogene confers a thermolabile phenotype to E26-transformed myeloid cells.
    Li RP; Duterque-Coquillaud M; Lagrou C; Debuire B; Graf T; Stehelin D; Leprince D
    Oncogene Res; 1989; 5(2):137-41. PubMed ID: 2608278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transformation by v-Myb.
    Lipsick JS; Wang DM
    Oncogene; 1999 May; 18(19):3047-55. PubMed ID: 10378700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biophysical and mutational analysis of the putative bZIP domain of Epstein-Barr virus EBNA 3C.
    West MJ; Webb HM; Sinclair AJ; Woolfson DN
    J Virol; 2004 Sep; 78(17):9431-45. PubMed ID: 15308737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.